Ambulatory blood pressure (BP) monitoring is the reference standard for out-of-clinic BP measurement. Thresholds for identifying ambulatory hypertension (daytime systolic BP [SBP]/diastolic BP [DBP] ≥135/85 mm Hg, 24-hour SBP/DBP ≥130/80 mm Hg, and nighttime SBP/ DBP ≥120/70 mm Hg) have been derived from European, Asian, and South American populations. We determined BP thresholds for ambulatory hypertension in a US population-based sample of African American adults.
T he 2015 US Preventive Services Task Force recommendation on screening for high blood pressure (BP) suggests using out-of-clinic BP measurements to confirm diagnoses of hypertension made in the clinic setting. 1 Ambulatory BP monitoring (ABPM) is the most commonly recommended approach for out-of-office BP measurement. 2, 3 In addition to confirming the diagnosis of hypertension, ABPM can be used to determine BP control among individuals taking antihypertensive medication as well as identify BP phenotypes, including masked and nocturnal hypertension. 3, 4 Several guidelines, scientific statements, and position papers have proposed BP thresholds for identifying ambulatory hypertension. 3, [5] [6] [7] [8] These thresholds were primarily derived from population-based studies of European, Japanese, and South American populations.
African Americans, a group with high risk for cardiovascular disease (CVD) outcomes, have higher mean daytime and nighttime ambulatory BP compared with whites. [9] [10] [11] The applicability of ABPM thresholds derived in European, Japanese, and South American populations to African American adults is unclear. In the current study, we used data from the Jackson Heart Study (JHS), a population-based cohort comprised exclusively of African American adults to determine ambulatory daytime, 24-hour, and nighttime BP thresholds that correspond to different clinic BP thresholds. In addition, we identified BP thresholds on ABPM that provide similar probability of CVD or all-cause mortality events as these clinic BP thresholds.
METHODS Study Population
The JHS is a population-based prospective cohort study designed to identify CVD risk factors among African American adults. 12 The JHS enrolled 5306 noninstitutionalized African American adults, ≥21 years of age, between 2000 and 2004. Participants were recruited from the Atherosclerosis Risk in the Community site in Jackson, MS, and a representative sample of urban and rural Jackson, Mississippi, metropolitan tricounty (Hinds, Madison, and Rankin Counties) residents, volunteers, randomly selected individuals, and secondary family members. 12, 13 The current analysis was restricted to 1148 JHS participants who completed ABPM as part of their baseline study visit (visit 1 2000-2004) . Participants (n=132) who did not meet the International Database on ABPM in relation to Cardiovascular Outcomes criteria for valid ABPM (n=102; described later) or who were missing information on clinic BP or antihypertensive medication use (n=30) were excluded from the analyses. After these exclusions were applied, the final analytic sample size was 1016 participants.
The institutional review boards of the University of Mississippi Medical Center, Jackson State University, and Tougaloo College approved the JHS protocol. The current analysis of JHS data was approved by the institutional review board at the University of Alabama at Birmingham. All participants provided written informed consent.
Data Collection
A detailed description of the methodology and data-collection procedures for the baseline visit in the JHS have been described elsewhere. [13] [14] [15] [16] [17] Briefly, data were collected during an in-home interview, by clinic examination, and by ABPM. ABPM was an optional procedure that participants were invited to complete. Of relevance to the current analysis, during the in-home interview, self-reported information was collected on sociodemographics, health behaviors (eg, alcohol consumption, current smoking), prior diagnoses of comorbid conditions, and antihypertensive medication use (see Methods in online-only Data Supplement). During the clinic examination, trained technicians measured height, weight, and BP; collected blood and urine samples; and conducted 2-dimensional echocardiography. Body mass index was calculated as weight in kilograms divided by height in meters squared. Using specimens collected during the study visit, low-density lipoprotein and high-density lipoprotein cholesterol, serum creatinine, urine albumin and creatinine, fasting serum glucose, and glycohemoglobin were measured. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation, 18 and albumin-to-creatinine ratio was also calculated. Diabetes mellitus was defined by a fasting blood glucose ≥126 mg/dL, glycohemoglobin ≥6.5%, or a prior diagnosis of diabetes mellitus with the use of glucose-lowering medication.
Clinic BP Measurement
Clinic BP was measured by trained staff using a random zero sphygmomanometer (Hawksley and Sons Ltd.) during the baseline
Clinical Perspective
What Is New?
• Ambulatory blood pressure monitoring (ABPM) is the most commonly recommended approach for out-ofoffice BP measurement.
• Several guidelines, scientific statements, and position papers have proposed BP thresholds for identifying ambulatory hypertension on ABPM.
• These thresholds were primarily derived from population-based studies of European, Japanese, and South American populations.
• We determined BP thresholds on ABPM for ambulatory hypertension in a US population-based sample of African American adults not taking and taking antihypertensive medication.
• The ambulatory BP thresholds identified for African American adults were higher than those from published recommendations.
What Are the Clinical Implications?
• The use of these ABPM thresholds in African American adults will lead to a lower prevalence of daytime, 24-hour, and nighttime hypertension, compared with using ABPM thresholds from published recommendations.
• Therefore, these findings have important clinical implications for the diagnosis and treatment of hypertension in African American adults. study visit. Each participant's right arm circumference was measured to determine the appropriate cuff size. After participants had rested for ≥5 minutes in an upright position with their back and arms supported, feet flat on the floor, and legs uncrossed, 2 BP measurements in the right arm, separated by 1 minute, were recorded. The mean of these clinic BP measurements was calculated. Quality control was conducted by the JHS Coordinating Center by monitoring digit preference for each staff member and by comparing the mean BP level measured within and between study staff. A BP comparability substudy was conducted, in which BP was measured simultaneously, using a Y connector, by random zero sphygmomanometer and an Omron HEM-907XL device, a semiautomated device. As described in Methods and Figure I in the online-only Data Supplement and in prior analyses of the JHS, the random-zero BP measurements were calibrated to the semiautomated device using robust regression. 13, 17 Elevated clinic BP was defined as mean clinic systolic BP (SBP) ≥140 mm Hg or mean clinic diastolic BP (DBP) ≥90 mm Hg.
Ambulatory BP Monitoring
After completing the clinic examination, participants were given the opportunity to complete ABPM for 24 hours. Participants who consented were fitted with an ABPM device (Spacelabs 90207, Spacelabs) on their nondominant arm. BP was recorded every 20 minutes. After 24 hours, the device was removed and data were downloaded onto a computer and processed with Medifacts International's Medicom software International Database on ABPM in relation to Cardiovascular Outcomes criteria were used to define a complete ABPM measurement, which is defined as ≥10 daytime (10:00-20:00) and ≥5 nighttime (00:00-06:00) SBP and DBP measurements. 19 The mean SBP and DBP levels were calculated for the daytime, nighttime, and 24-hour periods, separately.
CVD Events and All-Cause Mortality
The adjudication procedures for CVD events and all-cause mortality have been described previously. 20 Briefly, living participants or their proxies were contacted annually by telephone to assess potential CVD events and vital status. Hospital lists for discharges with specific diagnosis criteria were also obtained from the Jackson, Mississippi, tricounty area hospitals. Death certificates were requested from the Mississippi State Department of Health for JHS participants as needed. When a CVD-related hospitalization or death was identified, medical records were retrieved and abstracted. Trained clinicians adjudicated events following published guidelines using the information available about the circumstance surrounding an event. 20 For the current analysis, definite or probable CVD events (ie, coronary heart disease, nonfatal myocardial infarction, or acute coronary heart disease death or stroke defined as noncarotid embolic or thrombotic brain infarction, brain hemorrhage, or subarachnoid hemorrhage) and allcause mortality were available through December 31, 2012.
Statistical Analyses
Characteristics of the participants included in the analytic sample (n=1016), the sample who underwent ABPM but were excluded from the analysis (n=132), and non-ABPM sample (n=4158) were calculated. All subsequent analyses were weighted to the age and sex distribution of African American adults using data from the 2010 US Census. 21 Characteristics were calculated for the overall Characteristics are weighted to the age-sex distribution for the African American adult population using 2010 US census data. Unweighted characteristics for the overall sample (n=1016) are reported in Table I in the online-only Data Supplement. Values indicate mean±SD, unless otherwise indicated. HDL indicates high-density lipoprotein cholesterol; and LDL, low-density lipoprotein cholesterol.
sample and participants taking and not taking antihypertensive medication, separately. We used 3 approaches used in previous ABPM studies to identify thresholds for ambulatory hypertension: distribution-derived, regression-derived, and outcome-derived. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] All of these analyses were conducted stratified by antihypertensive medication use. The 3 approaches described for determining daytime BP thresholds were repeated for 24-hour and, separately, nighttime BP. All analyses were conducted using SAS version 9.4 (SAS Institute).
Distribution-Derived Approach
The goal of the distribution-derived approach is to identify percentiles of the BP distribution on ABPM for a population. 22, 24, 27, [30] [31] [32] The distributions of clinic and daytime SBP, and separately clinic and daytime DBP, were calculated. The 90th, 95th, and 99th percentiles of the daytime SBP and DBP distributions were identified using quantile regression. The 95% confidence interval was calculated by computing a Huber sandwich estimate using a local estimate of the sparsity function. The percentage of participants with clinic SBP ≥140 mm Hg and clinic DBP ≥90 mm Hg was calculated for those with daytime SBP and DBP greater than or equal to these BP percentiles.
Regression-Derived Approach
The goal of the regression-derived approach is to identify the BP levels on ABPM that correspond to specific clinic BP levels. 22, 23, 26, 29 Using the intercept and beta coefficient from a linear regression model with clinic SBP as the outcome and daytime Results are weighted to the age-sex distribution for the African American adult population using 2010 US census data. BP indicates blood pressure; and CI, confidence interval.
SBP as the independent variable, the level of daytime SBP and 95% confidence interval corresponding to clinic BP level of 140 mm Hg were identified. Distribution curves were plotted to show the percentage of participants with clinic SBP ≥140 mm Hg and with daytime SBP at or above the thresholds from ABPM corresponding to clinic SBP of 140 mm Hg. Daytime SBP levels corresponding to clinic SBP of 120 mm Hg, 130 mm Hg, and 160 mm Hg were also determined. We used the same approach to determine daytime DBP levels corresponding with clinic DBP of 80 mm Hg, 85 mm Hg, and 100 mm Hg.
Outcome-Derived Approach
The goal of the outcome-derived approach is to identify the threshold for ambulatory BP that corresponds to the same probability of an event associated with a clinic BP level (eg, SBP of ≥140 mm Hg). 25, 28 Higher clinic SBP was statistically significantly associated with the composite of CVD or allcause mortality (P<0.001), but clinic DBP was not (P=0.121). Therefore, thresholds for ambulatory SBP but not DBP thresholds were calculated. Thresholds for daytime SBP yielding similar 5-year predicted probability of a CVD event or all-cause mortality associated with clinic SBP ≥140 mm Hg were first calculated. To do this, we performed Cox regression with the composite outcome of CVD or mortality and clinic SBP as the independent variable. We identified the 5-year predicted probability of CVD or mortality for a clinic BP level of 140 mm Hg. Next, we conducted a Cox regression model with the outcome of CVD/all-cause mortality and daytime SBP as the independent variable. From this latter model, we determined the daytime SBP value that corresponded to the 5-year predicted probability of the outcome for a clinic SBP level of 140 mm Hg (ie, from the first Cox model described earlier). A bootstrap with 1000 data sets was used to calculate a 95% confidence interval for the daytime SBP yielding a similar 5-year predicted probability of the composite CVD/all-cause mortality outcome. Daytime SBP levels yielding similar 5-year predicted probability of an outcome associated with clinic SBP ≥120 mm Hg, ≥130 mm Hg, and ≥160 mm Hg were also calculated.
Comparisons With Recommended Ambulatory BP Thresholds
In scientific statements, guidelines, and position papers, ambulatory hypertension has been defined as having daytime SBP/ DBP ≥135/85 mm Hg, 24-hour SBP/DBP ≥130/80 mm Hg, and nighttime SBP/DBP ≥120/70 mm Hg. 3, [5] [6] [7] [8] We graphed the thresholds identified using the distribution-derived approach (95th percentile of BP), regression-derived approach (corresponding to clinic SBP/DBP of 140/90 mm Hg), and outcomederived approach (corresponding to clinic SBP of 140 mm Hg) and contrasted them with these previously published thresholds.
RESULTS
Characteristics of the JHS participants included in the analytic sample (n=1016), the sample who underwent ABPM but were excluded from the analysis (n=132) and non-ABPM sample (n=4158) are shown in Table I in the online-only Data Supplement. The mean age±SD of participants in the analytic sample weighted to the 2010 US African American adult population was 50.5±11.2 years; 55.2% were female and 38.9% were taking antihypertensive medication (Table 1) . Participants taking antihypertensive medication were older and more likely to be female, had less than a high school education, diabetes mellitus, estimated glomerular filtration rate <60 mL/min/1.73 m 2 , urine albumin-to-creatinine ratio ≥30 mg/g, and did not drink alcohol compared with those not taking antihypertensive medication. In addition, mean body mass index was higher, whereas low-density lipoprotein cholesterol was lower among those taking versus not taking antihypertensive medication. Clinic, daytime, nighttime, and 24-hour SBP were each higher among participants taking versus not taking antihypertensive medication, whereas no differences were present for DBP. Data represent ambulatory blood pressure thresholds (95% CI) corresponding to specified clinic SBP/DBP levels. Results are weighted to the age-sex distribution for the African American adult population using 2010 US census data. CI indicates confidence interval; DBP, diastolic blood pressure; and SBP, systolic blood pressure.
Distribution-Derived Approach to Determine Ambulatory BP Thresholds
Among participants not taking antihypertensive medication, the 90th, 95th, and 99th percentile thresholds for daytime SBP were 138 mm Hg, 144 mm Hg, and 158 mm Hg, respectively (Table 2) . Among participants at or above the 90th, 95th, and 99th percentile thresholds for daytime SBP, 47.6%, 55.9%, and 100.0% had clinic SBP ≥140 mm Hg, respectively. Among participants not taking antihypertensive medication, the 90th, 95th, and 99th percentile thresholds for daytime DBP was 91 mm Hg, 94 mm Hg, and 99 mm Hg, respectively. Among participants at or above the 90th, 95th, and 99th percentile thresholds for daytime DBP, 24.9%, 27.8%, and 55.1% had clinic DBP ≥90 mm Hg, respectively. The 90th, 95th, and 99th percentile thresholds for daytime, 24-hour, and nighttime SBP and DBP were higher for participants taking versus not taking antihypertensive medication.
Regression-Derived Approach to Determine Ambulatory BP Thresholds
Among participants not taking antihypertensive medication, daytime, 24-hour, and nighttime thresholds corresponding to clinic SBP/DBP of 140/90 mm Hg were 134/85 mm Hg, 130/81 mm Hg, and 123/73 mm Hg, respectively (Table 3) . A higher percentage of participants had daytime SBP ≥134 mm Hg, 24-hour SBP ≥130 mm Hg, and nighttime SBP ≥123 mm Hg than clinic SBP ≥140 mm Hg (Figure 1 ). Also, a higher percentage of participants had daytime DBP ≥85 mm Hg, 24-hour DBP ≥81 mm Hg, and nighttime DBP ≥73 mmHg than clinic DBP ≥90 mm Hg. Similar results were observed among participants taking antihypertensive medication ( Figure  II in the online-only Data Supplement). Daytime, 24-hour, and nighttime thresholds corresponding to clinic SBP/ DBP of 120/80 mm Hg, 130/85 mm Hg, and 160/100 mm Hg among participants not taking antihypertensive medication are shown in Table 3 and Figure 2 . Daytime, 24-hour, and nighttime SBP thresholds corresponding to clinic SBP of 120 mm Hg, 130 mm Hg, and 140 mm Hg were higher among participants taking versus those not taking antihypertensive medication (Table 3 and Figure  III in the online-only Data Supplement). Among participants taking versus those not taking antihypertensive medication, SBP thresholds corresponding to clinic SBP of 160 mm Hg were similar for the daytime and 24-hour period and higher for the nighttime period. Daytime, 24-hour, and nighttime DBP thresholds were similar among participants taking versus not taking antihypertensive medication. Figure 1 . Daytime, 24-hour, and nighttime blood pressure thresholds corresponding to a clinic systolic blood pressure/diastolic blood pressure threshold of 140/90 mm Hg determined using the regression-derived approach in participants not taking antihypertensive medication.
Dash line represents the distribution of ambulatory blood pressure. Solid line represents the distribution of clinic blood pressure. Light gray areas indicate the participants with daytime, 24-hour, and nighttime blood pressure at or above the thresholds corresponding to clinic systolic blood pressure/diastolic blood pressure of 140/90 mm Hg. Dark gray areas indicate the participants with clinic systolic blood pressure/diastolic blood pressure at or above the thresholds of 140/90 mm Hg.
Outcome-Derived Approach to Determine Ambulatory BP Thresholds
There were 165 events (n=80 CVD events and n=85 deaths) over a median 10.8 years of follow-up. The 5-year predicted probability of a CVD or an all-cause mortality event was higher at increasing levels of clinic SBP (Table 4) . Among participants not taking antihypertensive medication, daytime, 24-hour, and nighttime SBP thresholds corresponding to clinic SBP of 140 mm Hg were 138 mmHg, 134 mm Hg, and 129 mm Hg, respectively. Among participants taking antihypertensive medication, daytime, 24-hour, and nighttime SBP thresholds corresponding to clinic SBP of 140 mm Hg were 140 mm Hg, 137 mm Hg, and 133 mm Hg, respectively. Among participants taking versus not taking antihypertensive medication, daytime and 24-hour SBP thresholds were higher for clinic SBP thresholds of 160 mm Hg and similar for clinic SBP thresholds of 120 mm Hg and 130 mm Hg. Last, among participants taking versus not taking antihypertensive medication, nighttime SBP thresholds were higher for clinic SBP thresholds of 120 mm Hg, 130 mm Hg, and 160 mm Hg.
Comparisons With Published Recommendations
Thresholds defined by the 95th percentile of the population distribution and the outcome-derived approach were higher than those from published recommendations 3,5-8 for daytime, 24-hour, and nighttime BP among participants not taking and taking antihypertensive medication (Figure 3 and Figure IV in the online-only Data Supplement). Thresholds determined using the regression-derived approach were similar to published recommendations 3,5-8 for daytime and 24-hour BP and higher for nighttime BP among participants not taking and taking antihypertensive medication.
DISCUSSION
In the present study, we identified BP thresholds for ambulatory hypertension in a US population-based sample of African American adults not taking and taking antihy- Light gray area represents 95% confidence interval bands. Dark gray area represents 95% prediction bands. DBP indicates diastolic blood pressure; and SBP, systolic blood pressure.
pertensive medication using the distribution-, regression-, and outcome-derived approaches. The ambulatory BP thresholds identified for African American adults were higher than those from published recommendations, which were based on data from European, Japanese, and SouthAmerican populations.
3,5-8 Lines represent recommended systolic blood pressure and diastolic blood pressure thresholds. DBP indicates diastolic blood pressure; and SBP, systolic blood pressure.
Using the outcome-derived approach corresponding to a clinic SBP threshold of 140 mm Hg and regression-derived approach corresponding to a clinic DBP threshold of 90 mm Hg, we recommend defining daytime hypertension as mean daytime SBP/DBP ≥140/85 mm Hg, 24-hour hypertension as mean 24-hour SBP/DBP ≥135/80 mm Hg, and nighttime hypertension as mean nighttime SBP/DBP ≥130/75 mmHg in African American adults. The use of these BP thresholds, which are higher than those from published recommendations, will lead to a lower prevalence of daytime, 24-hour, and nighttime hypertension among African American adults. Consequently, the prevalence of white coat hypertension (ie, clinic hypertension without ambulatory hypertension) will increase and masked hypertension (ie, absence of clinic hypertension with ambulatory hypertension) will decrease.
An early method to derive ambulatory BP thresholds was the distribution-derived approach, commonly using the 95th percentile. 22, 24, 27, [30] [31] [32] In prior studies, thresholds using the distribution-derived approach have varied substantially from 1 another. 24, 27, [30] [31] [32] These divergent findings likely reflect differences in population characteristics, including the prevalence of clinic hypertension and whether the population was composed of individuals not taking and taking antihypertensive medication. Another issue with the distribution-derived approach is the assumption that a fixed percentage of the population has ambulatory hypertension. Given these limitations, the ambulatory BP thresholds we recommend do not take into consideration the thresholds determined using the distribution-derived approach.
There are several strengths of the current study. Few prior studies have conducted ABPM among African American adults, a population disproportionately affected by BP-related CVD compared with other racial/ethnic groups in the United States. The relatively large sample size with ABPM in the JHS allowed us to determine ABPM thresholds among participants taking and not taking antihypertensive medication, separately, and for a wide range of clinic BP levels. Despite these strengths, the results should be interpreted in the context of possible limitations. Only a subset of JHS participants underwent ABPM. Further, 2 clinic BP readings were obtained for each participant. The BP thresholds may have differed if ≥3 BP measurements were obtained at the baseline visit or serial clinic BP measurements were averaged across multiple visits. Also, clinic BP was measured using a random-zero sphygmomanometer among JHS participants. However, these measurements were calibrated to an oscillometric device. Further, the ABPM cuff was placed on the participant's nondominant arm to minimize the effect of daily activities on BP measurement (eg, writing, picking up objects), whereas clinic BP was measured in the right arm. Therefore, the present results may have been affected by interarm differences in BP measurements. Last, data were available only for African American adults. ABPM thresholds for whites, Hispanics, and Asians in the United States need to be identified among the same population to determine whether ambulatory BP thresholds differ by race/ethnicity.
In conclusion, the current study provides BP thresholds for identifying ambulatory hypertension in a US populationbased sample of African American adults not taking and taking antihypertensive medication. The following ambula- CI, confidence interval; and SBP, systolic blood pressure. Results are weighted to the age-sex distribution for the African American adult population using 2010 US census data.
tory hypertension definitions corresponding to clinic SBP/ DBP ≥140/90 mmHg are proposed: daytime hypertension defined as daytime SBP/DBP ≥140/85 mm Hg, 24-hour hypertension defined as 24-hour SBP/DBP ≥135/80 mm Hg, and nighttime hypertension defined as nighttime SBP/DBP ≥130/75 mm Hg. These thresholds differ from previously published recommendations, suggesting that there may be racial differences in thresholds for ambulatory BP.
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